Free Trial
NASDAQ:OKUR

OnKure Therapeutics (OKUR) Stock Price, News & Analysis

OnKure Therapeutics logo
$2.51 +0.01 (+0.40%)
Closing price 05/5/2025 04:00 PM Eastern
Extended Trading
$2.50 0.00 (-0.20%)
As of 08:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About OnKure Therapeutics Stock (NASDAQ:OKUR)

Key Stats

Today's Range
$2.44
$2.54
50-Day Range
$2.49
$5.19
52-Week Range
$2.42
$20.00
Volume
60,796 shs
Average Volume
81,003 shs
Market Capitalization
$33.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.33
Consensus Rating
Buy

Company Overview

OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO.

OnKure Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
61st Percentile Overall Score

OKUR MarketRank™: 

OnKure Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 411th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    OnKure Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    OnKure Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about OnKure Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for OnKure Therapeutics are expected to grow in the coming year, from ($4.05) to ($3.41) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of OnKure Therapeutics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of OnKure Therapeutics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    OnKure Therapeutics has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about OnKure Therapeutics' valuation and earnings.
  • Short Interest

    There is no current short interest data available for OKUR.
  • Dividend Yield

    OnKure Therapeutics does not currently pay a dividend.

  • Dividend Growth

    OnKure Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for OKUR.
  • News Sentiment

    OnKure Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for OnKure Therapeutics this week, compared to 1 article on an average week.
  • MarketBeat Follows

    Only 1 people have added OnKure Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, OnKure Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,749.00 in company stock.

  • Percentage Held by Insiders

    17.90% of the stock of OnKure Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    90.98% of the stock of OnKure Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about OnKure Therapeutics' insider trading history.
Receive OKUR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OnKure Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

OKUR Stock News Headlines

OnKure Therapeutics (OKUR) to Release Earnings on Tuesday
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.
What is Leerink Partnrs' Forecast for OKUR Q1 Earnings?
See More Headlines

OKUR Stock Analysis - Frequently Asked Questions

OnKure Therapeutics' stock was trading at $8.60 at the beginning of the year. Since then, OKUR stock has decreased by 70.8% and is now trading at $2.51.
View the best growth stocks for 2025 here
.

OnKure Therapeutics (NASDAQ:OKUR) released its quarterly earnings data on Tuesday, May, 6th. The company reported ($1.19) EPS for the quarter, topping the consensus estimate of ($1.41) by $0.22.

Shares of OKUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
3/10/2025
Today
5/05/2025
Next Earnings (Estimated)
5/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:OKUR
Previous Symbol
NASDAQ:OKUR
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$32.33
High Stock Price Target
$34.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+1,188.2%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-77,390,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$26.60 per share
Price / Book
0.09

Miscellaneous

Free Float
2,745,000
Market Cap
$33.72 million
Optionable
N/A
Beta
0.40
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:OKUR) was last updated on 5/6/2025 by MarketBeat.com Staff
From Our Partners